Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age.

Alcausin MB, Briody J, Pacey V, Ault J, McQuade M, Bridge C, Engelbert RH, Sillence DO, Munns CF.

Horm Res Paediatr. 2013;79(6):333-40. doi: 10.1159/000351374. Epub 2013 May 31.

PMID:
23735642
2.

Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.

Land C, Rauch F, Travers R, Glorieux FH.

Bone. 2007 Mar;40(3):638-44. Epub 2006 Nov 28.

PMID:
17127117
3.

Beneficial effects of intravenous pamidronate treatment in children with osteogenesis imperfecta under 24 months of age.

Kusumi K, Ayoob R, Bowden SA, Ingraham S, Mahan JD.

J Bone Miner Metab. 2015 Sep;33(5):560-8. doi: 10.1007/s00774-014-0618-2. Epub 2014 Oct 16.

PMID:
25319557
4.

Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.

Palomo T, Fassier F, Ouellet J, Sato A, Montpetit K, Glorieux FH, Rauch F.

J Bone Miner Res. 2015 Dec;30(12):2150-7. doi: 10.1002/jbmr.2567. Epub 2015 Jun 30.

5.

Cyclic pamidronate therapy in children with osteogenesis imperfecta.

Salehpour S, Tavakkoli S.

J Pediatr Endocrinol Metab. 2010 Jan-Feb;23(1-2):73-80.

PMID:
20432809
6.

Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation.

Andiran N, Alikasifoglu A, Gonc N, Ozon A, Kandemir N, Yordam N.

J Pediatr Endocrinol Metab. 2008 Jan;21(1):63-72.

PMID:
18404974
7.

The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.

Zeitlin L, Rauch F, Travers R, Munns C, Glorieux FH.

Bone. 2006 Jan;38(1):13-20. Epub 2005 Sep 12.

PMID:
16162424
8.

Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.

DiMeglio LA, Peacock M.

J Bone Miner Res. 2006 Jan;21(1):132-40. Epub 2005 Oct 17.

9.

Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.

Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, Hill SC, Gerber LH, Marini JC.

J Bone Miner Res. 2005 Jun;20(6):977-86. Epub 2005 Jan 18.

10.

Intravenous pamidronate in osteogenesis imperfecta type VII.

Cheung MS, Glorieux FH, Rauch F.

Calcif Tissue Int. 2009 Mar;84(3):203-9. doi: 10.1007/s00223-008-9211-9. Epub 2009 Jan 10.

PMID:
19137231
11.

Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment.

Land C, Rauch F, Munns CF, Sahebjam S, Glorieux FH.

Bone. 2006 Oct;39(4):901-6. Epub 2006 May 26.

PMID:
16730480
12.

Bone densitometry in pediatric patients treated with pamidronate.

Grissom LE, Kecskemethy HH, Bachrach SJ, McKay C, Harcke HT.

Pediatr Radiol. 2005 May;35(5):511-7. Epub 2005 Jan 18.

PMID:
15655696
13.

Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.

Atta I, Iqbal F, Lone SW, Ibrahim M, Khan YN, Raza J.

J Coll Physicians Surg Pak. 2014 Sep;24(9):653-7. doi: 09.2014/JCPSP.653657.

PMID:
25233970
14.

Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome.

Munns CF, Rauch F, Travers R, Glorieux FH.

J Bone Miner Res. 2005 Jul;20(7):1235-43. Epub 2005 Feb 21.

15.

Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.

DiMeglio LA, Ford L, McClintock C, Peacock M.

Bone. 2004 Nov;35(5):1038-45.

PMID:
15542028
16.

Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards.

Poyrazoglu S, Gunoz H, Darendeliler F, Bas F, Tutunculer F, Eryilmaz SK, Bundak R, Saka N.

J Pediatr Orthop. 2008 Jun;28(4):483-7. doi: 10.1097/BPO.0b013e318173a923.

PMID:
18520289
17.

Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.

Shapiro JR, Thompson CB, Wu Y, Nunes M, Gillen C.

Calcif Tissue Int. 2010 Aug;87(2):120-9. doi: 10.1007/s00223-010-9383-y. Epub 2010 Jun 11.

PMID:
20544187
18.

Pamidronate treatment of children with moderate-to-severe osteogenesis imperfecta: a note of caution.

Alharbi M, Pinto G, Finidori G, Souberbielle JC, Guillou F, Gaubicher S, Le Merrer M, Polak M.

Horm Res. 2009 Jan;71(1):38-44. doi: 10.1159/000173740. Epub 2008 Nov 27.

PMID:
19039235
19.

Two doses of pamidronate in infants with osteogenesis imperfecta.

Senthilnathan S, Walker E, Bishop NJ.

Arch Dis Child. 2008 May;93(5):398-400. Epub 2007 Dec 18.

PMID:
18089634
20.

Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age.

Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH.

J Clin Endocrinol Metab. 2000 May;85(5):1846-50.

PMID:
10843163

Supplemental Content

Support Center